FPE026 / FAPON - LARVOL DELTA

A next-generation CD8-selective tri-specific T cell engager targeting CDH17 with enhanced efficacy and reduced toxicity (AACR 2026) - "Furthermore, FPE026 demonstrates significant anti-tumor activity in the AsPC-1 subcutaneous xenograft model, with limited cytokine elevation in serum. Together, these findings highlight FPE026 as a promising next-generation TCE candidate that combines enhanced CD8+ T cell selectivity and potent anti-tumor efficacy with an improved safety profile."

Clinical • Trispecific • Oncology • CD4 • CD8 • CDH17 • IL6 • NKG2D • TNFA